(An Open-ended Pharma Sector Scheme.) The primary investment objective of the Scheme is to generate consistent returns by investing in equity / equity related or fixed income securities of Pharma and other associated companies. Related Links Fund Manager Addenda KIM cum Application Form Latest NAVs Scheme Current NAV Nav Date Dividend Plan 36.0058 26 Mar 2010 Growth Plan Bonus Option 48.2784 26 Mar 2010 Growth Plan Growth Option 48.2784 26 Mar 2010 Performance as on 26/02/2010 Absolute Compounded Annualized 6 months 1 year 3 year 5 year Since Inception Reliance Pharma Fund - Growth 34.82 147.43 29.08 28.25 29.17 BSE-HC 26.09 88.44 10.68 13.53 14.67 Past Performance may or may not be sustained in the future. Aforesaid returns are Compounded annualized returns in % of Growth Option. (Inception Date:08/06/2004) Calculations assume that all payouts during the period have been reinvested in the units of the scheme at the then prevailing NAV. Product Features Investment Objective - The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies Asset Allocation Indicative asset allocation Types of Instruments Risk Profile (% of total assets) Maximum Most Likely Minimum Equity and Equity related Instruments 100% 80% 0% High to Medium Debt Instruments & Money Market Instruments with an average maturity OF 5-10 yrs 100% 20% 0% Medium to Low Securitised debt upto 100% of the corpus. However, the above is only indicative and the AMC reserves the right to change the profile based on market outlook and the interest rate scenario. Fund Manager - Mr. Sailesh Raj Bhan Plans Available Growth Plan: Growth Option & Bonus Option Dividend Plan: Dividend payout Option & Dividend Reinvestment Option Benchmark Index - BSE Health Care Index Minimum Application Amount Rs 5000 and in multiples of Re. 1 thereafter Minimum additional purchase amount Rs 1000 and in multiples of Re. 1 thereafter Load Structure: Entry Load In terms of SEBI circular no. SEBI/IMD/CIR No.4/ 168230/09 dated June 30, 2009, no entry load will be charged by the Scheme to the Nil investor effective August 1, 2009. Upfront commission shall be paid directly by the investor to the AMFI registered Distributors based on the investors' assessment of various factors including the service rendered by the distributor Exit Load If redeemed or switched out on or before completion of 1 year from the date of allotment of units. 1% If redeemed or switched out after completion of 1 year from the date of allotment of units Nil Facilities Available Systematic Investment Plan Systematic Transfer Plan Systematic Withdrawal Plan Reliance Salary AddVantage Dividend Transfer Plan Recurring Investment Plan for Corporate Employees Trigger Facility Online Transaction Reliance SIP Insure Auto Debit & Electronic Clearing System Applicable NAVs Subscriptions/Purchases including switch - ins: In respect of valid applications received upto 3 p.m. by the Mutual Fund alongwith a local cheque or a demand draft payable at par at the place where the application is received, the closing NAV of the day on which application is received shall be applicable. In respect of valid applications received after 3 p.m. by the Mutual Fund alongwith a local cheque or a demand draft payable at par at the place where the application is received, the closing NAV of the next business day shall be applicable. Redemptions including switch - outs: In respect of valid applications received upto 3 p.m. by the Mutual Fund, closing NAV of the day of receipt of application, shall be applicable. In respect of valid applications received after 3 p.m. by the Mutual Fund, the closing NAV of the next business day shall be applicable. Disclaimer Sponsor: Reliance Capital Limited. Trustee: Reliance Capital Trustee Co. Limited. Investment Manager:Reliance Capital Asset Management Limited. Statutory Details: The Sponsor, the Trustee and the Investment Manager are incorporated under the Companies Act 1956. Risk Factors Mutual Funds and securities investments are subject to market risks and there is no assurance or guarantee that the objectives of the Scheme will be achieved. As with any investment in securities, the NAV of the Units issued under the Scheme can go up or down depending on the factors and forces affecting the capital markets. Past performance of the Sponsor/AMC/Mutual Fund is not indicative of the future performance of the Scheme. The Sponsor is not responsible or liable for any loss resulting from the operation of the Scheme beyond their initial contribution of Rs.1 lakh towards the setting up of the Mutual Fund and such other accretions and additions to the corpus. Reliance Pharma Fund is the name of the Scheme and does not in any manner indicate either the quality of the Scheme; its future prospects or returns.The NAV of the Scheme may be affected, interalia, by changes in the market conditions, interest rates, trading volumes, settlement periods and transfer procedures. The Mutual Fund is not assuring that it will make periodical dividend distributions, though it has every intention of doing so. All dividend distributions are subject to the availability of distributable surplus in the Scheme. Please read the Statement of Additional Information and Scheme Information Document carefully before investing.